Carboplatin

A large number of analogues have been subject to clinical trials but only carboplatin has emerged as a viable clinical candidate. All platinum compounds possess 'leaving groups' that are substituents on the platinum atom that are lost when DNA-platinum cross-links are formed. Physical properties for analogues suggests a correlation between reactivity of leaving groups and nephrotoxicity.

There is still a degree of controversy regarding the clinical equivalence of cisplatin and carboplatin; there are limited situations such as germ cell tumours where cisplatin still appears to be the agent of choice. However, carboplatin in most other circumstances has supplanted the use of cisplatin.

0 0

Post a comment